Elucid Secures Fifth Medicare Contractor for AI Coronary Plaque Coverage

Elucid has announced that Noridian will begin covering AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ™ image analysis software, starting December 8, 2024. With this decision, five out of seven Medicare Administrative Contractors (MACs) will offer coverage for this…

Read MoreElucid Secures Fifth Medicare Contractor for AI Coronary Plaque Coverage

Jupiter Endovascular Treats First U.S. Patient with Vertex Pulmonary Embolectomy System

Jupiter Endovascular, Inc., a medical technology startup focused on pioneering endovascular procedures with its Endoportal Control™ platform, has announced the successful treatment of the first U.S. patient in the SPIRARE II pivotal study. This study evaluates the Vertex Pulmonary Embolectomy…

Read MoreJupiter Endovascular Treats First U.S. Patient with Vertex Pulmonary Embolectomy System

Siemens Healthineers to Automate Patient Testing, Addressing Lab Workflow and Staffing Issues

Siemens Healthineers is revolutionizing clinical lab automation by consolidating 25 tasks typically performed manually by staff, significantly reducing manual workflow steps by 75%. Traditional lab automation relies on a track system to transport samples, but the Atellica Integrated Automation system…

Read MoreSiemens Healthineers to Automate Patient Testing, Addressing Lab Workflow and Staffing Issues

CVS Health Foundation Addresses Care Barriers for Chronic Disease Patients in Atlanta

The CVS Health® Foundation has announced a $1.5 million funding initiative to enhance access to healthcare services, medically tailored meals, and transportation for chronic disease patients in Atlanta. This funding will support partnerships with Good Samaritan Health Center, Open Hand…

Read MoreCVS Health Foundation Addresses Care Barriers for Chronic Disease Patients in Atlanta

Maze Therapeutics Announces Positive Phase 1 Results for MZE829 in APOL1 Kidney Disease

Maze Therapeutics, a biopharmaceutical company focused on developing precision medicines using human genetics, has announced positive results from the Phase 1 clinical trial of MZE829 in healthy volunteers. MZE829 is an oral small molecule that inhibits APOL1, which Maze is…

Read MoreMaze Therapeutics Announces Positive Phase 1 Results for MZE829 in APOL1 Kidney Disease

Pharmacy Automation Innovations Reduce Operational Costs

Amid fluctuating market conditions and regulatory changes, pharmacies can leverage automated production to enhance efficiency, boost profitability, and substantially lower operational costs. Pharmacy automation provider JFCRx™ has launched TruCard™, a multi-dose adherence blister card packaging and inspection system designed to…

Read MorePharmacy Automation Innovations Reduce Operational Costs